Literature DB >> 1117420

Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man.

M G Myers, P J Lewis, J L Reid, C T Dollery.   

Abstract

Intracerebroventricular (ICV) injection of propranolol in the dog, cat and rabbit produces a significant fall in arterial pressure. In the following experiments, regional brain propranolol concentrations and changes in mean arterial pressure (MAP) have been measured in the rabbit after central and peripheral administration of the drug and the results compared to human brain/plasma levels. In the conscious rabbit, ICV injection of l-propranolol (500 mug) produced a prolonged fall in MAP, maximal at 105 minutes (16.8 plus or minus 5.9 mm Hg below base line). The regional brain propranolol concentrations after ICV injection of 14C-dl-propranolol (530 mug) were determined and the levels compared to those achieved following i.v. infusion of the unlabeled drug (1.0 and 2.0 mg/kg/hr). The propranolol concentrations in the hypothalamus, medulla pons and midbrain after i.v. infusion were similar to the propranolol content in these areas at 60 and 120 minutes after ICV injection. Intravenous infusion of propranolol also resulted in significant falls in MAP between 60 and 120 minutes. In control studies, infusions of d-propranolol (1.0, 2.0 and 4.0 mg/kg/hr), which is virtually devoid of beta adrenoceptor blocking activity, produced only slight reductions in MAP. Postmortem studies in patients treated with prolonged i.v. infusions of d-propranolol as part of the treatment of paraquat poisoning indicate that the brain/plasma concentration of propranolol in man is similar to that observed in the rabbit. Propranolol is therefore highly concentrated in human brain tissue and comparable brain levels in the rabbit result in a hypotensive response.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1117420

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

2.  Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension.

Authors:  H M Brecht; F Banthien; W Schoeppe
Journal:  Klin Wochenschr       Date:  1976-11-15

3.  Editorial: Clinical aspects of the blood-brain barrier.

Authors: 
Journal:  Br Med J       Date:  1976-07-17

4.  Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol.

Authors:  E B Erdtsieck-Ernste; M G Feenstra; M H Botterblom; J De Barrios; G J Boer
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 5.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 6.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

7.  Cerebrospinal fluid concentration of metoprolol in a hypertensive patient.

Authors:  A J WOOD
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

8.  Beta-blocker brain concentrations in man.

Authors:  J M Cruickshank; G Neil-Dwyer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  The effects of atenolol on spontaneous and reflex activity of the sympathetic nerves in the anaesthetized cat.

Authors:  E M Scott
Journal:  Br J Pharmacol       Date:  1981-07       Impact factor: 8.739

10.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.